Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Inderal LA, Inderal XL, Inderal, Propranolol Hydrochloride ER, Hemangeol
Synonyms :
Inderal, Inderal XL
Class :
Non-cardio-selective beta blocker, Group II antiarrhythmics
Brand Name :
Inderal LA, Inderal XL, Inderal, Propranolol Hydrochloride ER, Hemangeol
Synonyms :
Inderal, Inderal XL
Class :
Non-cardio-selective beta blocker, Group II antiarrhythmics
ADULT DOSING
Dosage Forms & Strengths
Oral solution:
20mg/5ml
40mg/5ml
Injectable solution:
1mg/ml
Tablet:
10,20,40,60,80mg
Capsule, extended-release
60,80,120,160mg
Immediate dose:
40
mg
Tablet
Orally
every 12 hrs
Do not exceed 640mg/day
Dose Adjustments
Maintenance dose:80-240mg orally, every 8-12 hours
Oral solution
4.28mg/ml
20mg/5ml
40mg/5ml
Tablet
10,20,40,60,80mg
Initial dose:
0.6
mg
Tablet
Orally
every week
Maintenance dose:1.7mg/kg for two weeks
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
may increase the AV blocking effect of alpha2 agonists
methyldopa/hydrochlorothiazide
may increase the AV blocking effect of alpha2 agonists
may increase the AV blocking effect of alpha2 agonists
may enhance the serum concentration of rizatriptan
may decrease the bronchodilatory effect when combined
dronedarone: they may increase the bradycardic effect of Beta-Blockers
tasimelteon: they may decrease the therapeutic effect of Beta-Blockers
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the effects of indomethacin by pharmacodynamic antagonism
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
beta2 agonist bronchodilation may be reduced with beta2 blockers
beta2 agonist bronchodilation may be reduced with beta2 blockers
beta2 agonist bronchodilation may be reduced with beta2 blockers
beta2 agonist bronchodilation may be reduced with beta2 blockers
beta2 agonist bronchodilation may be reduced with beta2 blockers
may decrease the therapeutic effect of activated charcoal
may decrease the bronchodilatory effect of Beta2 agonists
rivastigmine: they may increase the bradycardic effect of Beta-Blockers
may diminish the effects of indomethacin by pharmacodynamic antagonism
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may increase the effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the hypoglycemic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
It may diminish the serum concentration when combined with bile acid sequestrants
It may enhance the effects when combined with chloroprocaine by pharmacodynamic synergism
antipsychotic agents increase the effect of beta-blockers
antipsychotic agents increase the effect of beta-blockers
antipsychotic agents increase the effect of beta-blockers
antipsychotic agents increase the effect of beta-blockers
antipsychotic agents increase the effect of beta-blockers
when bromazepam and propranolol are used together, there is a potential reduction in the bromazepam's metabolism
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with antidiabetic agents
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
when combined, the antihypertensive effect of Beta-Blockers can be reduced with NSAIDs
when combined, the antihypertensive effect of Beta-Blockers can be reduced with NSAIDs
when combined, the antihypertensive effect of Beta-Blockers can be reduced with NSAIDs
when combined, the antihypertensive effect of Beta-Blockers can be reduced with NSAIDs
when combined, the antihypertensive effect of Beta-Blockers can be reduced with NSAIDs
may diminish the bronchodilatory effect when combined with beta2-agonists
may diminish the bronchodilatory effect when combined with beta2-agonists
may diminish the bronchodilatory effect when combined with beta2-agonists
beta blockers: they may increase the therapeutic effect of acetylcholine inhibitors
beta blockers: they may increase the therapeutic effect of acetylcholine inhibitors
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
ascorbigen, when used in combination with propranolol, the efficacy of propranolol is lowered
CYP1A2 inhibitors increase the concentration of propranolol in serum
may enhance the adverse/toxic effect of lacosamide
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-Blockers decrease the efficacy of dobutamine
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may increase the bradycardic effect
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect of beta2 agonists
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may increase the toxic effect of cholinergic agonists
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the serum concentration of lidocaine
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may decrease the therapeutic effect of epinephrine
may increase the hypoglycaemic effect when combined
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the bradycardic effect of Acetylcholinesterase Inhibitors
may decrease the bronchodilatory effect when combined
amiodarone: they may increase the bradycardic effect of Beta-Blockers
dipyridamole: they may increase the bradycardic effect of Beta-Blockers
disopyramide: they may increase the bradycardic effect of Beta-Blockers
dobutamine: they may decrease the therapeutic effect of Beta-Blockers
epinephrine: they may decrease the therapeutic effect of Beta-Blockers
epinephrine (racemic): they may decrease the therapeutic effect of Beta-Blockers
etilfrine: they may increase the bradycardic effect of Beta-Blockers
lidocaine: they may enhance the serum concentration of Beta-Blockers
mavacamten: they may increase the toxic effect of Beta-Blockers
methacholine: they may increase the toxic effect of Beta-Blockers
nifedipine: they may increase the hypotensive effect of Beta-Blockers
reserpine: they may increase the hypotensive effect of Beta-Blockers
succinylcholine: they may increase the neuromuscular-blocking effect of Beta-Blockers
theophylline: they may decrease the bronchodilatory effect of Beta-Blockers
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
Individuals taking beta-blocking drugs may exhibit a diminished response to standard doses of epinephrine if it becomes necessary to manage an adverse allergic reaction
the bradycardic activity of propranolol may be increased
may decrease the antihypertensive effect when combined with beta-blockers
may enhance the effects of the other by pharmacodynamic synergism
Propranolol is a non-selective beta-adrenergic receptor blocker, used in treatment of hypertension, angina, and various cardiac arrhythmias.
Frequency defined:
>10%
Bronchiolitis
Sleep disorders
1-10%
Abdominal pain
Diarrhea
Drowsiness
Fatigue
Nightmares
Irritability
<1%
Alopecia
2nd-degree atrioventricular blockage
Do not discontinue therapy without the advice of a health care provider.
Be cautious with patients suffering from compensated heart failure, hepatic impairment, Pheochromocytoma.
Pediatric patients: Innopran XL is not suggested to use.
Pregnancy consideration: The drug doesn’t cause major harm
Pregnancy category: US FDA Category- C
Lactation: The release of the drug in human breast milk is in low quantities.
Pregnancy category:
Pharmacodynamics:
Propranolol blocks beta-1 and beta-2 adrenergic receptors by reducing the effects of catecholamines. This leads to decreased heart rate, myocardial contractility, and blood pressure.
Pharmacokinetics:
Absorption:
Propranolol has moderate oral bioavailability (25-35%).
Distribution:
Propranolol has a large volume of distribution (~4 L/kg) indicating extensive tissue penetration.
Metabolism:
Propranolol undergoes extensive metabolism in liver by cytochrome P450 enzymes and particularly CYP2D6.
Excretion:
Metabolites of propranolol are primarily excreted via urine with less than 1% excreted unchanged.
It is administered orally in the form of tablet.
Patient information leaflet
Generic Name: Propranolol
Pronounced: pro-PRAN-oh-lol
Why do we use propranolol?
Propranolol treats chest pain(angina), high blood pressure(hypertension), tremors, and heart rhythm disorders.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
